Anavex Life Sciences Corp
Închisă
SectorSănătate
3.34 1.83
Rezumat
Modificarea prețului
24h
Minim
3.2800000000000002
Maxim
3.39
Venit | 4.1M -5.7M |
|---|---|
EPS | -0.06 |
Angajați | 34 |
EBITDA | -821K -6.5M |
Următoarele câștiguri | 11 aug. 2026 |
|---|
Capitalizare de piață | 42M 273M |
|---|---|
Deschiderea anterioară | 1.51 |
Închiderea anterioară | 3.34 |
Sentimentul știrilor
By Acuity
86%
14%
321 / 340 Clasament în Healthcare
Anavex Life Sciences Corp Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Anavex Life Sciences Corp Așteptări
Sentiment
By Acuity
321 / 340 Clasament în Sănătate
Sentimentul știrilor
Evidențe foarte puternice de scădere
Volatilitate
Sub medie
Volumul știrilor (RCV)
Peste medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
